

#### <sup>30</sup>**Abstract**

### <sup>31</sup>**Background**

32 High throughput 16S rRNA gene sequencing and enhanced culture methods (e.g., expanded 33 quantitative urine culture, EQUC) have established the existence of the human bladder <sup>34</sup>microbiome. We aim to test the hypothesis that the bladder environment of patients with chronic 35 kidney disease (CKD) differs from that of unaffected controls with associated consequences for 36 the composition of the bladder microbiome.

### <sup>37</sup>**Methods and Materials**

38 Females ( $n=66$ ) and males ( $n=66$ ) diagnosed with CKD and age-BMI-matched healthy control 39 (HC) females  $(n=22)$  and males  $(n=22)$  were recruited. Transurethral catheterized urine was 40 collected for 16S rRNA gene sequencing and Expanded Quantitative Urine Culture (EQUC). <sup>41</sup>Fecal samples also were sequenced. Urinary analysis, kidney function and serum cytokines were 42 examined.

### <sup>43</sup>**Results**

<sup>44</sup>Bladder microbiomes of CKD females and males versus HC females and males differed <sup>45</sup>(FDR<0.05); however, the difference was more obvious in females. In CKD females, sequencing <sup>46</sup>revealed depletion of 5 genera, including *Lactobacillus*, and enrichment of 14 genera, including <sup>47</sup>*Escherichia/Shigella*, *Bifidobacterium*, and several clostridial genera (FDR<0.05), while EQUC <sup>48</sup>detected increased *Escherichia* and decreased *Lactobacillus* CKDB(P<0.05). *Escherichia-Shigella* <sup>49</sup>was positively, whereas *Lactobacillus* was negatively, associated with CKDB-female serum 50 creatinine (r=0.285, P=0.020; r=-0.337, P=0.006, respectively). *Lactobacillus* was positively 51 associated with eGFR (r=0.251, P=0.042). Some CKD-related serum cytokines were negatively 52 associated with clostridial genera. In contrast, the fecal microbiomes of CKD and HC females and 53 males did not significantly differ in bacterial diversity or composition. However, bladder and fecal <sup>54</sup>microbiomes of CKD females resembled each other more than those of controls, as assessed by 55 the Bray-Curtis Dissimilarity Index (FDR<0.05).

#### <sup>56</sup>**Conclusions**

<sup>57</sup>CKD bladder microbiomes were dysbiotic, which was more obvious in females. This dysbiosis <sup>58</sup>was associated with kidney damage severity and dysregulation of serum cytokines. The increased

- 59 similarity between bladder and fecal microbiomes of CKD females suggests possible
- <sup>60</sup>"gut-leakage."
- <sup>61</sup>**Key words**
- 62 bladder; chronic kidney disease; cytokine; fecal microbiome; kidney function; microbiome

#### <sup>63</sup>**1 Introduction**

<sup>64</sup>Chronic kidney disease (CKD) is a non-communicable disease that affects more than 10% of 65 the general population worldwide<sup>[1]</sup>. It is a progressive disease that over time leads to irreversible 66 nephron loss and kidney failure. However, CKD is uncured by current therapies, possibly due to 67 its unclear pathology. Previous studies found that microbial dysbiosis in human gut and blood is 68 associated with CKD[2, 3], and crosstalk between host and microbiome is pathophysiologically 69 relevant to CKD $[2, 3]$ .

70 The human bladder harbors its own microbial community $[4-8]$ . Most studies have explored <sup>71</sup>associations between the microbiomes of urine samples obtained by transurethral catheter (bladder) 72 or midstream void (urogenital) and urinary tract disorders, such as urinary stone disease[9], 73 urinary tract infection (UTI)[10], and bladder cancer[11]. One study assessed the urogenital <sup>74</sup>microbiome in CKD patients and found it to be extremely diverse with greater diversity associated 75 with estimated glomerular filtration rate (eGFR). However, this study did not include controls and 76 analyzed voided urine samples $[12]$ , which often contains microbes from both the urinary and 77 genital tracts $[13, 14]$ .

78 Kidneys are a major site for elimination of many cytokines. The delicate equilibrium of 79 proinflammatory cytokines and their inhibitors is dysregulated in CKD[15], and associated with 80 gut dysbiosis in CKD[16, 17]. For example, the dysregulation of tumor necrosis factor (TNF- $\alpha$ ) 81 and interleukin-6 (IL-6) is associated with gut dysbiosis in CKD[16, 17].

82 With mounting evidence of an interaction between gut microbiome and kidney function, some 83 researchers have proposed a gut-kidney axis[18, 19]. However, these researchers ignored the 84 possible existence of microbiomes in the urinary tract  $[20, 21]$ . Given that microbes are exquisitely 85 sensitive to their environments and are known to interact with their niches, we hypothesize that (1) <sup>86</sup>CKD patients have a dysbiotic bladder microbiome, (2) the bladder microbiome distinguishes 87 CKD patients better than the fecal microbiome, and (3) the bladder microbiome is associated with 88 serum cytokines.

### <sup>89</sup>**2 Materials and methods**

### <sup>90</sup>*2.1 Study participant recruitment*

91 Participants were recruited from July  $1<sup>st</sup>$  2018 to March 30<sup>th</sup> 2020. **Figure S1** displays the study

92 design, including participant recruitment, methods, and objectives. Diagnostic criteria of CKD 93 included decreased eGFR  $\sim$   $(60 \text{ mL/min}/1.73 \text{ m}^2)$  or evidence of kidney damage, such as 94 albuminuria (albumin excretion rate  $\geq$ 30 mg/24 h; urinary albumin creatinine ratio [UACR]  $\geq$ 30  $95$  mg/g], urine sediment abnormalities, electrolyte and other abnormalities due to tubular disorders, 96 abnormalities detected by histology, and/or structural abnormalities detected by imaging or history 97 of kidney transplantation[22]. CKD patients undergoing hemodialysis were excluded. 98 Asymptomatic controls ("healthy" controls, HC) were recruited if they had an eGFR≥90 99 ml/min/1.73m<sup>2</sup> and were free of current renal damage, a history of liver disease, cancer, diabetes, 100 hypertension, and hyperlipidemia. After recruitment, HC subjects were excluded if they had an 101 indicator of urinary tract infection (UTI) by urinalysis, such as >5 WBCs/HPF, >3 RBCs/HPF, 102 positive urine nitrites, positive leucocyte esterase, positive occult, positive protein, and abnormal 103 values of diabetes, hypertension, hyperlipidemia. Any participant with acute intercurrent disease 104 or infection, diarrhea, kidney transplantation, pregnancy, breastfeeding was excluded. Those who 105 used antibiotics, probiotics or immunosuppressive drugs within 30 days before enrollment also 106 were excluded.

### <sup>107</sup>*2.2 Urine collection and storage*

108 Bladder urine samples were collected by transurethral catheterization and stored as reported 109 previously $[23]$ . Before catheter insertion, 5% iodophor was applied to disinfect the genital and 110 perineal areas. Fifty mL urine were obtained and separated into three portions (i.e., 30 mL, 5 mL 111 and 15 mL) that were used for 16S rRNA gene sequencing, Expanded Quantitative Urine Culture <sup>112</sup>(EQUC) and clinical urinary analysis[4], respectively. All samples were processed in a biosafety 113 cabinet. Samples for 16S rRNA gene sequencing and EQUC were placed in sterile, DNA- and 114 enzyme-free centrifuge tubes. Samples for 16S rRNA gene sequencing were stored at  $-80^{\circ}$ C 115 refrigerator within 15 mins after collection. Samples for EQUC were placed in an insulated sterile 116 container, immediately cooled on ice, and transferred to the research personnel within 4 hours.

### <sup>117</sup>*2.3 Expanded Quantitative Bladder Urine Culture*

118 Methods for EQUC were modified according to previous studies [6, 24]. 0.1 mL of catheterized 119 bladder urine was inoculated onto BAP, chocolate and colistin, as well as nalidixic acid agars 120 (Kemajia inc., Shanghai, China), streaked for quantification, and incubated in 5%  $CO<sub>2</sub>$  at 35°C for

<sup>121</sup>48h. Next, 0.1 mL of urine was inoculated onto two CDC anaerobe 5% sheep blood agar plates 122 and incubated in an anaerobic incubator with a Campy gas mixture (5%  $O_2$ , 10% CO<sub>2</sub>, 85% N<sub>2</sub>) at 123  $35^{\circ}$ C for 5 days. 1.0 mL of urine was placed in thioglycolate medium and incubated aerobically at 124  $35^{\circ}$ C for 5 days. If growth was visually detected in the thioglycolate medium, the medium was 125 mixed, and 0.01 mL of urine was plated on BAP and CDC anaerobe 5% sheep blood agars for 126 isolation and incubated aerobically and anaerobically at  $35^{\circ}$ C for 48h. Each morphologically <sup>127</sup>distinct colony type was isolated on a different plate of the same media to prepare a pure culture 128 that was used for identification, as described below.

<sup>129</sup>*2.4 16S rRNA gene sequencing* 

130 Bacterial DNA isolation from urine was described previously $[6, 24]$ . The quantity and quality 131 of the extracted DNA was measured using a NanoDrop ND-1000 spectrophotometer (Thermo <sup>132</sup>Fisher Scientific, Waltham, MA, USA) and agarose gel electrophoresis. Using the isolated DNA as 133 the template, the bacterial 16S rRNA V3-V4 region was PCR-amplified for 32 cycles using <sup>134</sup>universal primers 338F and 806R. The resultant PCR amplicons were purified with Agencourt 135 AMPure XP Beads (Beckman Coulter, Indianapolis, IN, USA) and quantified using the PicoGreen 136 dsDNA Assay Kit (Invitrogen, Carlsbad, CA, USA). Amplicon pools were prepared for 137 sequencing, and the size and quantity of the amplicon library were assessed using an Agilent 2100 138 Bioanalyzer (Agilent, Santa Clara, MA, USA) and Library Quantification Kit for Illumina (Kapa 139 Biosciences, Woburn, MA, USA), respectively. The libraries were sequenced using the NovaSeq <sup>140</sup>6000 platform. As urines are low-biomass samples, they were sequenced in duplicate for <sup>141</sup>reproducibility. When the Bray-Curtis dissimilarity of the duplicated urinary microbiome samples 142 was above 0.3[25], they were re-sequenced. If their Bray-Curtis dissimilarity remained above 143 0.3[25], they were removed from further analysis. Six negative controls (2 without urine, 2 144 without bacterial DNA, and 2 without PCR product) also were sequenced.

<sup>145</sup>*2.5 Bioinformatic analysis of 16S rRNA gene sequencing data* 

146 Raw reads of the 16S rRNA gene sequences were trimmed using Cutadapt <sup>147</sup>(cutadapt.readthedocs.io) to remove barcodes and adaptors. The overlapping paired-end reads 148 were merged into a longer tag using FLASH (v1.2.8). Reads were quality trimmed using fdtrim <sup>149</sup>(v0.94) from the 3' end to remove bases with low-quality scores. Reads shorter than 100bp, with

150 more than 5% Ns, or with an average quality below 20 were discarded. Chimeras were removed 151 using Vsearch (v2.3.4). QIIME2 was used to process the clean reads to generate an ASV table, and 152 taxonomy of microbes was identified using the Silva database  $(v138)$ . Environmental 153 contaminants of urine samples were removed as previously described[20]. Bacterial ASVs whose 154 counts did not exceed five times the maximum number of counts in the negative controls were 155 considered as contaminates and removed, as described[20]. We also manually removed bacteria 156 that have been reported to be environmental contaminants from soil and water.

### <sup>157</sup>*2.6 Identification of bacterial isolates*

### <sup>158</sup>*2.6.1 16S rRNA gene sequencing of bacterial isolates*

159 Bacterial isolates purified as described above were harvested: if the colonies were large enough, 160 a single colony was chosen; if not, then the plate was scraped. To the harvested bacteria, 200µL 161 lysis buffer (Guhe, Hangzhou, China) was added and its DNA extracted using the method 162 described above for 16S rRNA gene sequencing. Identification of the isolates was confirmed by 163 partial sequencing of the 16S rRNA gene. Briefly, the 16S rRNA gene was amplified for 30 cycles <sup>164</sup>by PCR with universal primers 27F and 1492R, which results in an amplicon of approximately 165 1500 bp. PCR was performed in a DNA thermocycler (Thermo Scientific, USA) with PCR Premix <sup>166</sup>(Ensure biologicals, Shanghai, China) in 50 μL reaction mixtures. The resultant amplicons were 167 sequenced with the ABI Prism<sup>TM</sup> Bigdye<sup>TM</sup> terminator cycle sequencing reaction kit (Applied 168 Biosystems, USA) using the 27F and 1492R primer pair. The sequencing product was purified 169 using the Millipore-Montage dye removal kit (Ensure Biologicals, Shanghai, China) and 170 sequenced on an ABI 3730XL capillary DNA sequencer (Applied Biosystems, USA). For each run, 171 negative controls containing water instead of template DNA were run in parallel. All sequencing 172 procedures were performed by BGI (Shanghai, China). For taxonomic identification, a portion of 173 the sequence was compared to sequences in GenBank public database <sup>174</sup>(http://www.ncbi.nlm.nih.gov/BLAST/).

### <sup>175</sup>**2.6.2 MALDI-TOF MS identification of bacterial isolates**

176 When a bacterial isolate could not be identified by 16S rRNA gene sequencing, we used 177 Matrix-Assisted Laser Desorption Ionization-Time-Of-Flight Mass Spectrometry (MALDI-TOF 178 MS), as described previously<sup>[4]</sup>. Briefly, a small portion of a single colony was overlaid with 1 µL

179 of a saturated solution of alpha-cyano-4-hydroxycinnamic acid matrix in 50% acetonitrile and 2.5% <sup>180</sup>trifluoroacetic acid (VITEK MSCHCA, bioMérieux), then air dried. *Escherichia coli* (ATCC 8739) 181 was used for system calibration. Mass spectra were acquired using a VITEK MS Plus (bioMérieux, 182 Marcy l'Etoile) and the bioMérieux VITEK MS (IVD Knowledgebase v.3.2) used to analyze a 183 composite mass spectrum for accurate identification. A probability score between 60% and 99.9% <sup>184</sup>was considered to be a high discrimination value and thus a reliable identification. A probability 185 score <60% was considered to be a low discrimination identification. No identification resulted 186 when either no match was found for the composite spectra, or the analysis did not obtain enough 187 spectral peaks[26]. Isolates that yielded no identification results were redeposited on the target 188 plate and reanalyzed.

### <sup>189</sup>*2.7 Other sample collection and processing*

190 Blood samples for assessment of renal function and serum cytokines were collected on the day 191 of urinary sample collection. The Bio-Plex<sup>TM</sup> 200 System (Bio-Rad) and Bio-Plex Pro<sup>TM</sup> Human <sup>192</sup>Cytokine Screening 48-plex Panel (Bio-Rad, California, USA) were used to detect serum 193 cytokines. An aliquot of bladder urine (described above) was used for urinalysis. The 24-hour 194 urine volume was collected one day prior to the day of bladder microbiome sample collection. <sup>195</sup>Fecal samples were collected on the day of bladder urine sample collection. The participants were 196 told to excrete their feces into a sterile container. A nurse then put 30 mg feces into a sterile tube 197 using sterile technique and stored them at -80°C refrigerator within 15 mins of collection. DNA 198 isolation and sequencing of fecal samples was the same as for the urine samples, except that they <sup>199</sup>were sequenced only once, as we have found that Bray-Curtis values for feces samples are 200 typically  $< 0.3$ .

### <sup>201</sup>*2.8 Disease profiles assessment*

<sup>202</sup>Participants' demographics data were collected during a face-to-face interview. Blood pressure 203 and fasting blood glucose were assessed on the day of urine and fecal sample collection.

### <sup>204</sup>*2.9 Statistical analysis*

<sup>205</sup>Pearson's Chi-square or Fisher's exact tests were used with categorical variables; Student's *<sup>t</sup>* 206 test was used on normalized continuous variables and Wilcoxon rank-sum test was used on 207 non-normal continuous variables. The *P*-value was adjusted for multiple comparisons using the

- 208 Benjamini–Hochberg (BH) false discovery rate (FDR). The significance threshold was set at an
- 209 FDR-corrected value <0.05. Pearson correlation analysis was used to assess associations between
- 210 variables, and the significance threshold was set at a P value  $<0.05$ .
- <sup>211</sup>**3 Results**
- <sup>212</sup>**3.1 Participants**

<sup>213</sup>Figure **S1** displays the process, including participant recruitment, methods, and study objectives. 214 Briefly, we collected urine samples through sterilized catheter from 230 CKD patients and 176 215 controls. All participants with catheterized urine (i.e., bladder) samples with bacterial DNA below 216 the level of detection and control participants with abnormal urinalysis values were removed from 217 downstream analysis. To ensure reproducibility, bladder urine samples were sequenced in 218 duplicate, and participants whose samples were dissimilar (i.e., had a Bray-Curtis Dissimilarity 219 score above 0.3) were removed from downstream analysis. From the remaining participants, 220 age/BMI-matched CKD and HC males and females, resulting in 66 bladder urine samples from 221 CKD males (CKDB-male) and 22 bladder samples from HC males (HCB-male) and 66 bladder 222 samples from CKD females (CKDB-female) and 22 urine samples from HC females 223 (HCB-female).

224 Compared to the HCB groups, both the male and female CKDB groups had higher rates of 225 hypertension and diabetes, as well as higher rates of occult blood and cast in their urine (Fisher's 226 exact test, P<0.05; **Table 1**). Although both male and female CKDB groups had higher levels of 227 systolic blood pressure than those in controls, only female patients had a higher level of diastolic <sup>228</sup>blood pressure than that in controls (*t*-test, P<0.05; **Table 1**). Compared to HCB-males and 229 HCB-females, the CKDB-males and CKDB-females had lower levels of eGFR and higher levels 230 of serum creatinine, whereas the CKDB-males had a higher level of blood urea nitrogen and <sup>231</sup>CKDB-females had a higher level of uric acid (*t*-test, P<0.05; **Table 1**). No difference was found 232 in the nutrient intake between the groups of CKD and HC (*t*-test, P<0.05, **Table S1**); thus, it was 233 not considered to be a confounding factor in downstream analyses.

### <sup>234</sup>**3.2 Bladder microbiomes are altered in CKD males and females**

<sup>235</sup>As gender difference has been reported to impact the bladder microbiome in asymptomatic 236 subjects and disease groups $[27, 28]$ , we wondered whether the bladder microbiome composition

237 of females and males differed between our CKDB and HCB groups. To test this, we performed 238 principal-coordinate analysis (PCoA) of Bray-Curtis Dissimilarity indices for all microbial taxa <sup>239</sup>(ASVs) present within and among the microbiomes of each group. As expected, the bladder 240 microbiome of HCB-males and HCB-females was significantly separated  $(R^2=0.077, FDR=0.002;$ <sup>241</sup>**Figure 1A**); the bladder microbiome of CKDB-males and CKDB-females was also separated but 242 less so  $(R^2=0.017, FDR=0.016;$  **Figure 1A**). Since the bladder microbiome of males and females 243 differed, further analyses were performed separately.

<sup>244</sup>When comparing CKDB to HCB, we found that the bladder microbiomes of both males and 245 females differed (PERMANOVA,  $R^2=0.033$ , FDR=0.001 and  $R^2=0.072$ , FDR<0.001, respectively; <sup>246</sup>**Figure 1A**). Hypertension, glucocorticoid levels, hypoglycemia and hypolipidemic agents were 247 not confounding factors, as bladder microbiome of the medication users and gender-age matched 248 non-users did not differ (PERMANOVA, FDR>0.05; Figure S2A-D). The bladder microbiome of <sup>249</sup>CKDB-males and CKDB-females was significantly more diverse than those of their respective <sup>250</sup>HCB controls. For females, this was reflected in both the number ASVs (**Figure 1B**) and the Chao <sup>251</sup>1 index, which estimate bacterial richness (Wilcoxon rank*-*sum test, FDR<0.001; **Figure 1C**); for 252 males, this increased richness was reflected only in the number of ASVs (Figure 1B). To assess 253 whether bacterial richness was associated with renal function in CKDB females, we performed a 254 Pearson correlation analysis between Chao1 and estimators of renal function (i.e., eGFR, serum 255 creatinine, blood urea nitrogen, and serum uric acid), but no association was observed (P $>0.05$ ).

### <sup>256</sup>**3.3 Bladder microbiome composition is altered in CKD patients**

257 Proteobacteria, Firmicutes, Actinobacteriota, Bacteroidota and Fusobacteriota were the 5 most 258 abundant phyla in the bladder microbiomes of all 4 groups (**Figure 1D**). After correction for 259 multiple testing, we observed no significant difference when we compared CKDB-males and <sup>260</sup>HCB-males, and CKDB-females and HCB-females (Wilcoxon rank-sum test, FDR>0.05; **Table**  261 S2 & S3). Notably, at the genus level, both the CKDB-males and CKDB-females were enriched <sup>262</sup>for *Escherichia-Shigella* (9.59% and 17.71%, respectively), and *Enterococcus* (3.34% and 5.63% 263 respectively; **Figure 1E**). Next, we compared bacterial genera that accounted for  $>0.1\%$  of the 264 total relative abundance in males and females. After correction for multiple testing, we observed 265 no significant difference when we compared CKDB-males and HCB-males (Wilcoxon rank-sum

266 test, FDR>0.05; **Table S4**). In contrast, 19 genera differed significantly between CKDB-females 267 and HCB-females (Wilcoxon rank-sum test, FDR<0.05; **Table S5**). Five genera were significantly 268 less abundant in CKDB-females relative to HCB-females (Wilcoxon rank-sum test, FDR<0.05). <sup>269</sup>These included one unknown genus in the family Comamonadaceae and the genera *Lactobacillus,*  <sup>270</sup>*Sphingobium*, *Sphingomonas*, and *Streptomyces* (**Table S5**; **Figure 2A**). Fourteen genera were 271 significantly more abundant in CKDB-females, including *Escherichia-Shigella*. Others included <sup>272</sup>*Agathobacter*, *Anoxybacillus*, *Bacteroides*, *Bifidobacterium*, *Blautia*, *Comamonas*, <sup>273</sup>*Diaphorobacter*, [Eubacterium] coprostanoligenes group, *Faecalibacterium*, CAG-352 in the <sup>274</sup>family Ruminococcaceae, *Sphingobacterium*, and *Subdoligranulum* (Wilcoxon rank-sum test, <sup>275</sup>FDR<0.05; **Table S5**; **Figure 2B**). Many of these taxa are members of the class Clostridia. As <sup>276</sup>*Escherichia-Shigella* is one of most common causes of UTI[29, 30], and the participants with 277 current UTI were excluded, we compared the abundance of *Escherichia-Shigella* between the 278 age-matched CKDB-female urine samples with positive urinary leucocyte esterase and negative 279 ones but there was no significant difference between the positive samples and negative ones <sup>280</sup>(29.82±45.23 vs. 24.73±39.24 (Wilcoxon rank-sum test, P=0.781, FDR=0.814). In addition, since <sup>281</sup>*Lactobacillus* can impede *Escherichia* growth in the urinary tract[31], we performed Pearson 282 correlation analysis to examine whether they were connected but there was no significant 283 correlation (r=-0.221, P=0.075).

<sup>284</sup>To determine whether the detected sequences came from live bacteria, we performed EQUC <sup>285</sup>(**Table S6**), an enhanced culture method that vastly outperforms the standard clinical microbiology 286 urine culture method $[4, 32]$ . Microbes (including both bacteria and fungi) were more prevalent in 287 HCB-females than in HCB-males (68.2 vs 13.6%, P<0.001; Table S7), whereas microbes were 288 only slightly more prevalent in CKDB-females than in CKDB-males (51.1 vs 42.4%, P=0.295; <sup>289</sup>**Table S8**). Microbes also were more prevalent in CKDB-males than in HCB-males (42.2 vs. 290 13.6%, P=0.014; **Table S9**). In contrast, microbes were equally prevalent in CKDB-females and 291 HCB-females (51.5 vs 68.2%, P=0.173; **Table S10**).

292 Only two identified genera and one unidentified genus were detected in HCB-males: the fungus <sup>293</sup>*Cladosporium* was detected in one (4.5%), the bacterium *Curtobacterium* was detected in another <sup>294</sup>(4.5%), and an unidentified genus was detected in a third (4.5%). In contrast, multiple genera were

detected in CKDB-males. The most prevalent genera were *Bacillus* [18.18% (11/66)], *Staphylococcus* [9.09% (6/66)], *Kocuria* [3.03% (2/66)], *Micrococcus* [3.03% (2/66)], and *Paenibacillus* [3.03% (2/66)]. The genus *Bacillus* was significantly more prevalent in the 298 CKDB-males relative to HCB-males (Fisher's exact test, P=0.031; Figure 3A).

<sup>299</sup>Although the overall prevalence of microbes did not differ between HCB-females and <sup>300</sup>CKDB-females, many genera differed (**Figure 3B**). The most prevalent in HCB-females were <sup>301</sup>*Bacillus* [22.73% (5/22)], *Lactobacillus* [22.73% (5/22)], and *Herbaspirillum* [13.64% (3/22)],

<sup>302</sup>whereas the most prevalent in CKDB-females were *Bacillus* [15.15% (10/66)], *Escherichia* [7.58%

<sup>303</sup>(5/66)], and *Rothia spp*. [4.55% (3/66)]. The genera *Lactobacillus* and *Herbaspirillum* were

304 significantly less prevalent in CKDB-females than in HCB-females (Fisher's exact test, P<0.05;

<sup>305</sup>**Figure 3B**).

### <sup>306</sup>**3.4 Altered genera in CKD was associated with demographics and renal function**

307 Because the bladder microbiome composition of CKDB-females and HCB-females differed, we 308 used Pearson correlation analysis to determine whether any of the significantly different taxa (as 309 determined by 16S rRNA gene sequencing) were associated with any demographic category or 310 renal function. For CKDB-females, multiple associations were observed (Figure 4A). For 311 example, *Escherichia-Shigella* was positively associated with CKDB-female serum creatinine <sup>312</sup>(r=0.285, P=0.020). *Lactobacillus* was negatively associated with CKDB-female age and serum 313 creatinine (r=-0.330, P=0.007 and r=-0.337, P=0.006; respectively), but positively associated with <sup>314</sup>CKDB-female eGFR (r=0.251, P=0.042). *Bifidobacterium* was positively associated with 315 CKDB-female disease duration  $(r=0.335, P=0.006)$ . In contrast, significant associations were not 316 observed for HCB-females (r<0.03, P>0.05; Figure 4B), with one exception: *Streptomyces* was 317 positively associated with blood urea nitrogen ( $r=0.790$ , P<0.001).

### <sup>318</sup>**3.5 Bacterial community altered in all stages of CKD patients**

319 For each CKD stage, we performed PCoA of Bray-Curtis Dissimilarity indices, comparing their 320 bladder microbiomes to gender- and age-matched controls; these microbiomes differed 321 significantly in stages 2-5 (PERMANOVA, FDR<0.05), but not stage 1 (PERMANOVA, <sup>322</sup>FDR>0.05; **Figure S3A**). These differences were primarily due to changes in composition, as only <sup>323</sup>CKDB microbiomes from stages 3 and 5 were significantly richer than their respective HCB (as

<sup>324</sup>measured by Chao 1; Wilcoxon rank*-*sum test, FDR<0.05) and the Shannon indices did not differ

<sup>325</sup>(**Figure S3B**).

### <sup>326</sup>**3.6 Altered bladder microbiome associated with altered serum cytokines in CKD patients**

327 To determine if associations exist between the bladder microbiome and serum cytokines, we 328 first measured serum cytokines and then compared them to the bladder microbiome. Of the 48 329 serum cytokines we assessed, 44 cytokines were detected. Of these, 23 cytokines differed 330 significantly between the 66 CKD females and 22 female controls (Wilcoxon rank-sum test, <sup>331</sup>FDR<0.001). Some, such as IL-8, IL-18, IL-1β and TNF-α were increased in CKD females, <sup>332</sup>whereas others, such as IL-9 and TNF-β were decreased in CKD females (**Figure 5A**). To <sup>333</sup>determine whether associations existed between serum cytokines and bladder microbial 334 composition, we performed Pearson correlation analysis. Several taxa enriched in HCB-females <sup>335</sup>were negatively associated with increased serum cytokines (r>0.03, P<0.05; **Figure 5B**). For 336 example, the genera *Sphingobium* and *Streptomyces* were negatively associated with IL-18, IL-8, <sup>337</sup>and/or IL-1β. In contrast, several taxa enriched in CKDB-females were positively associated with <sup>338</sup>increased levels of serum cytokines (r>0.03, P<0.05; **Figure 5B**). For example, *Bifidobacterium* 339 was positively associated with IL−2Rα, and MIG (r>0.03, P<0.05), and IL-8 was positively 340 associated with the members of Clostridia, including *Agathobacter*, *Blautia*, *Faecalibacterium*, <sup>341</sup>*Subdoligranulum* (r>0.03, P<0.05). Intriguingly, the genus *Lactobacillus* was enriched in <sup>342</sup>HCB-females but none of the correlations were statistically significant (**Figure 5B**).

### <sup>343</sup>**3.7 Alteration of microbiome not observed in feces**

<sup>344</sup>To assess the gut-bladder axis in CKD, we assessed the fecal and bladder microbiomes of 345 CKD-males ( $n=10$ ) to age-matched HC-males ( $n=10$ ) and CKD-females ( $n=22$ ) with age-matched <sup>346</sup>HC-females (n=22) who provided both fecal and catheterized urine samples. We observed no 347 difference in gut microbiome compositions (PERMANOVA, FDR>0.05; Figure 6A) or alpha 348 diversity (Wilcoxon rank-sum test, FDR>0.05; Figure 6B) between fecal samples from CKD 349 males (CKDF-males) and fecal samples from HC males (HCF-males) or between fecal samples 350 from CKD females (CKDF-females) and fecal samples from HC females (HCF-females). To test 351 the hypothesis that gut-kidney leakage occurs in CKD patients, we first performed PCoA on the 352 bladder and fecal microbiomes in CKD patients and controls; the bladder microbiomes differed

<sup>353</sup>significantly from the corresponding fecal microbiomes for both CKD-males and females and 354 their age-matched HC-controls (PERMANOVA, FDR<0.05; **Figures 6C-6F).** We then compared 355 the Bray-Curtis dissimilarity between the bladder and gut microbiomes from either CKD 356 males/females or HC males/females. These microbiomes tended to be less dissimilar in <sup>357</sup>CKD-females than in HC-females (Wilcoxon rank-sum test, FDR<0.001), but not in the males <sup>358</sup>(Wilcoxon rank-sum test, FDR>0.05; **Figure 6G**). In addition, the Bray-Curtis dissimilarity 359 between the bladder and gut microbiomes from CKD females was slightly less than that from 360 CKD males (0.965±0.068 vs. 0.983±0.048, Wilcoxon rank-sum test, FDR=0.089), while the 361 Bray-Curtis dissimilarity between the bladder and fecal microbiomes from healthy females was 362 almost equal to that from healthy males  $(0.998\pm0.005 \text{ vs. } 0.998\pm0.004, \text{ Wilcoxon rank-sum test},$ 363 FDR=0.472).

## <sup>364</sup>**Discussion**

365 The role of a balanced intestinal microbiome in maintaining kidney function is widely  $366$  recognized[2]; however, the role of the bladder microbiome in kidney functions remains 367 understudied. This study is the first to reveal that CKD patients possess a distinct bladder 368 microbiome, and that the bladder microbial profile is associated with unbalanced kidney function 369 and dysregulated serum cytokine profiles.

370 First, we found that both male and female CKD patients had dysbiotic bladder microbiomes, as 371 assessed by 16S rRNA gene sequencing. This dysbiosis may be associated with loss of kidney 372 function, as the bladder microbiomes of CKD patients in stages 2-5 differed from those of controls. <sup>373</sup>A similar phenomenon in the gut was described by Wu et al., who reported that the fecal 374 microbiome could reflect the CKD stage[33].

375 We observed an increased microbial richness in CKD patients relative to controls and found that 376 this increase was greater in females than in males, as assessed by both sequencing and EQUC. 377 Since population-based studies show that CKD affects more females than males[34], bladder 378 dysbiosis in the context of CKD sex differences is worthy of future exploration.

379 One striking finding of this study is that CKD females' bladder microbiome was enriched for 380 the genus *Escherichia/Shigella*, as assessed by both 16S rRNA gene sequencing and EQUC. This 381 genus was not associated with urinary leucocyte esterase or serum cytokine profile, but its

382 increase in CKD females was positively correlated to the level of serum creatinine, a kidney 383 function estimator. Given that *Escherichia/Shigella* is the most commonly detected genus in <sup>384</sup>UTI[29, 30], its increased prevalence at relatively high abundance in CKD females indicate that 385 this potentially uropathogenic microbe should be a concern during treatment of CKD.

386 Another notable finding of this study is that both detection methods (sequencing and EQUC) <sup>387</sup>revealed a depletion of *Lactobacillus* in CKD females. Decreased *Lactobacillus* has been reported <sup>388</sup>in patients with UTI[35], and may be a sign of an unhealthy bladder. Even though we did not 389 observe an association between *Lactobacillus* and serum cytokines like previous urinary 390 microbiome studies on interstitial cystitis and systemic lupus erythematosus suggested[20, 36], <sup>391</sup>*Lactobacillus* was associated with the kidney function indicators. It was positively associated with <sup>392</sup>eGFR and negatively associated with serum creatinine, indicating that *Lactobacillus* in the bladder <sup>393</sup>may be a biomarker for kidney function. Although the effects of bladder *Lactobacillus* on kidney 394 functions have never been reported, *Lactobacillus* oral supplementation in mouse models has been 395 suggested to attenuate the loss of kidney function, in a process that involved inflammation 396 pathways[37, 38]. Thus, *Lactobacillus* in the bladder might protect kidney function in females.

<sup>397</sup>While decreased *Lactobacillus* in the vagina is a well-documented feature of older females, 398 recent studies have shown this decrease to also be true of the bladder. Komesu et al. found that the 399 relative abundance of *Lactobacillus* in catheterized urine had a strong negative relationship with 400 age when study participants with mixed urinary incontinence and controls were assessed <sup>401</sup>together[39]. Another study demonstrated that *Lactobacillus* in mid-stream voided urine was more 402 common in pre-menopausal females comparing to post-menopausal ones[40]. In contrast, our <sup>403</sup>study found a negative association between bladder *Lactobacillus* and age only in female CKD 404 patients. This finding suggests that loss of kidney function, a sign of getting older[41], may be <sup>405</sup>attributable to *Lactobacillus* depletion.

<sup>406</sup>*Bifidobacterium* is widely advocated as a probiotic due to its potential beneficial effects[42]. 407 However, in our study, bladder *Bifidobacterium* was enriched in CKD females and positively <sup>408</sup>associated with disease duration and MIG, a chemoattractant cytokine for activated T lymphocytes 409 and tumor infiltrating T-lymphocytes[43], and an indication of an unhealthy kidney, e.g. kidney 410 cancer or stones<sup>[44, 45]. Increased *Bifidobacterium* also has been reported in patients with kidney</sup>

411 stones<sup>[21]</sup>. *Bifidobacterium* has been reported in bladder infections and other diseases [46-48].

<sup>412</sup>Therefore, it is unclear whether *Bifidobacterium* in the bladder serves as a probiotic or not.

413 The upregulation of IL-1β, IL-8, IL-18 and TNF- $\alpha$  in CKD patients have been reported[49-51]. <sup>414</sup>As expected, all these cytokines were upregulated in the serum of CKD females, and almost all <sup>415</sup>were negatively associated with decreased *Sphingobium* in CKD female bladders. As *Sphingobium* 416 has been rarely reported, the roles of these associations remain to be examined in the future. It is 417 worth noting that half of the bacterial genera enriched in CKD females are members of the class <sup>418</sup>Clostridia, including *Agathobacter*, *Blautia*, *Faecalibacterium* and *Subdoligranulum*, and all were 419 positively linked to the increase of the level of IL-18 in patients. Some members of Clostridia, 420 including Clostridiales, Lachnospiraceae and Ruminococcaceae, have been reported to be enriched 421 in the voided urine of patients with chronic prostatitis[52]. It is reasonable to conclude that 422 Clostridia plays a pathogenic role in CKD females.

<sup>423</sup>To explore the gut-kidney axis, we assessed the fecal and bladder microbiomes in <sup>424</sup>age-gender-matched CKD patients and controls. We only observed a statistical difference in the 425 bladder microbiome. Using the Bray-Curtis Dissimilarity Index, we compared the fecal and 426 bladder microbiomes and observed a statistically significant decrease in the female CKD patients 427 but not in the matched controls, supporting the hypothesis that "gut-leakage" may occur in CKD 428 females.

429 Our study has limitations. First, the number of CKD patients and age-gender-BMI matched 430 controls were unequal with a 3:1 patient:control ratio. Thus, there may exist additional 431 confounders that vary within the patients and controls[53]. However, kidney-age-related problems 432 are one of the most common health issues in elderly population [41], so it was difficult to recruit <sup>433</sup>healthy matched controls. Second, we only enrolled from a single institution which cannot 434 appropriately power the genetic profiles [54].

435 In summary, our study shows that the bladder microbiome of patients with CKD differs 436 significantly from that of the controls, especially in females. The bladder microbiomes of CKD 437 patients are richer (i.e., include more taxa) and many of those taxa are distinctly different in 438 prevalence and abundance between two groups. Both 16S rRNA gene sequencing and EQUC <sup>439</sup>detected a significant increase of *Escherichia*/*Shigella* and a significant decline of *Lactobacillus* in



### <sup>446</sup>**Declarations**

### <sup>447</sup>**Ethics approval and Consent to participate**

- <sup>448</sup>The ethics committee of the Affiliated Wuxi Second Hospital of Nanjing Medical University
- <sup>449</sup>approved the study (Ref. 2018051). Informed consent was provided by all subjects prior to sample
- 450 collection.

#### <sup>451</sup>**Consent for publication**

452 All authors consent to the publication of this manuscript.

#### <sup>453</sup>**Availability of data and materials**

- 454 Raw data from 16S rRNA sequencing are available in the Sequence Read Archive under
- <sup>455</sup>BioProject ID SRP360378 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA807874).

### <sup>456</sup>**Competing interests**

- 457 All authors declare that they have no competing interests.
- <sup>458</sup>**Funding**
- <sup>459</sup>Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project
- <sup>460</sup>(THRCJH20200901); Wuxi "key medical discipline construction" Municipal Clinical Medical
- 461 Center (municipal public health center) Project (LCYXZX202103); Wuxi Technological Project
- <sup>462</sup>(N20192047); Zhejiang Provincial Natural Science Foundation of China (LXR22H160001);
- 463 National Natural Science Foundation of China (81874142 and 82073041).
- 464 Authors' contributions
- 465 Conceptualization: Fengping Liu, Alan J. Wolfe, Wei Chen, and Ninghan Feng; methodology:
- <sup>466</sup>Fengping Liu, Jingjie Du, Qixiao Zhai, Hao Lin, Yifan Xu, Feng Yan, Yang Wang, Wei Guo,
- 467 Zhenyi Xu, Jialin Hu, Peng Jiang, Chaoqun Gu, Jiayi Sheng, Lei Hu; software: Fengping Liu, and
- <sup>468</sup>Jingjie Du; validation: Alan J. Wolfe; writing: Alan J. Wolfe, Fengping Liu, Jingjie Du, Yifeng
- <sup>469</sup>Gu; supervision: Alan J. Wolfe; funding acquisition: Ninghan Feng; project administration:
- 470 Fengping Liu, Jialin Hu, Lei Hu, Peng Jiang, Jiayi Sheng, Chaoqu Gu, Yang Wan, FengYan, Hao
- 471 Lin, Shichao Wei.

### <sup>472</sup>**Acknowledgements**

- 473 We gratefully acknowledge the volunteers who participated in our study.
- <sup>474</sup>**Authors' information**

- 475  $\frac{1}{\text{Wuxi}}$  School of Medicine, Jiangnan University, Wuxi, Jiangsu, China
- 476  $\degree$  2 Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University
- 477 Chicago, Maywood, Illinois, USA
- <sup>3</sup> Department of Urology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi,
- 479 Jiangsu, China
- 480<sup>4</sup> Department of Nephrology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi,
- 481 Jiangsu, China
- <sup>5</sup> Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key
- <sup>483</sup>Laboratory for Diagnosis and Treatment of Infectious Diseases, School of Medicine, The First
- <sup>484</sup>Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
- 485 <sup>6</sup> State Key Laboratory of Food Science and Technology and School of Food Science and
- 486 Technology, Jiangnan University, Wuxi, Jiangsu, China

### <sup>488</sup>**Legends**

- <sup>489</sup>**Table 1 Demographics of urine donors of CKD patients and controls**
- 490 Pearson Chi-square or Fisher's exact test was used with categorical variables; Student's t test on normalized
- 491 continuous variables was used.
- 492

<sup>493</sup>**Figure 1** Bacterial composition, Venn, bacterial diversity, and phylum and genus composition in the urine from 494 CKD patients and HC. (A) PCoA based on Bray-Curtis distances ASV level showed different microbial 495 compositions between groups of CKDB-females and HCB-females, and between CKDB-males and HCB-males. 496 The 95% confidence ellipse is drawn for each group. Permutational multivariate analysis of variance <sup>497</sup>(PERMANOVA) was performed for statistical comparisons of samples in the two groups. *P* value was adjusted by 498 the Benjamini and Hochberg false discovery rate (FDR). **(B)** Venn diagrams were made to compare the ASV 499 composition within different groups. Each intersection of a number of areas represents the number of ASVs, which <sup>500</sup>are present in all the intersecting areas. **(C)** Bacterial richness and diversity measured by Chao 1 and Shannon 501 index were calculated at ASV level. Wilcoxon rank-sum test was performed and adjusted by Benjamini and Hochberg false discovery rate (FDR). \*\*\*,  $P_{\text{adj}}$  < 0.001. **(D)** Microbial profile at the phylum and genus level. Only 503 the top 5 most abundant phylum and the top 15 most abundant genus are shown.



507

- <sup>508</sup>**Figure 2** Bacterial genera that were differentially abundant between CKD patients and controls. **(A)** Bacterial <sup>509</sup>genera significantly decreased in CKDB-females comparing to those in HCB-females. **(B)** Bacterial genera 510 significantly increased in CKDB-females comparing to those in HCB-females. P value was calculated using 511 Wilcoxon rank-sum test and adjusted by Benjamini and Hochberg FDR. \*, FDR < 0.05; \*\*, FDR<0.01; and \*\*\*, 512 FDR< 0.001.
- <sup>513</sup>Abrreviations: CKDB-female: urine samples provided by females with CKD; CKDB-male: urine samples 514 provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-female: urine 515 samples provided by healthy males.

516

- <sup>517</sup>**Figure 3** Comparisons of numbers of subjects with visible bacterial isolates between groups of patient and HC. 518 Chi-square/Fisher's test was used, P values that are significant at 0.05. Bars represent the prevalence of isolates in 519 each group.
- <sup>520</sup>Abrreviations: CKDB-female: urine samples provided by females with CKD; CKDB-male: urine samples 521 provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-female: urine 522 samples provided by healthy males.

<sup>524</sup>**Figure 4** Bladder microbiome was associated with participants' demographics and kidney function estimators. **(A)**  525 The heatmap depicted the association between the bacterial genera showing differed in CKDB-female and 526 CKD-female's demographics and kidney function estimators. **(B)** The heatmap depicted the association between 527 the bacterial genera showing differed in HCB-female and HC-female's demographics and kidney function 528 estimators. Pearson correlation analysis was performed. The correlation of two variables with values of  $|r|>0.3$  and <sup>529</sup>*P<*0.05 are displayed. \*, *P<*0.05; \*\*, *P<*0.01; and \*\*\*, *P<*0.001.

<sup>531</sup>**Figure 5** Serum cytokines profiles in CKD females and their associations to urinary microbiome. **(A)** Serum 532 cytokines increased and decreased in CKD females compared to controls. *P* value was calculated using Wilcoxon

rank-sum test and adjusted by Benjamini and Hochberg false discovery rate (FDR). **(B)** Pearson correlation analysis was performed on the bacterial genera and cytokines that differed between the CKD females and controls. 535 The correlation of two variables with values of  $|r|>0.3$  and  $P\Box < \Box 0.05$  are displayed. \*,  $P\Box < \Box 0.05$ ; \*\*,  $P\Box < \Box 0.01$ ; and \*\*\*,  $P\Box < \Box 0.001$ .

<sup>537</sup>Abrreviations: CKDB-female: urine samples provided by females with CKD; CKDS-female: serum samples 538 provided by females with CKD; HCB-female: urine samples provided by healthy females; HCS-female: serum 539 samples provided by healthy females.

<sup>541</sup>**Figure 6** Comparisons of microbiomes in feces and urine in CKD males and females. **(A)** PCoA based on 542 Bray-Curtis distances ASV level showed different microbial compositions between groups of CKDF-females and 543 HCF-females, and between CKDF-males and HCF-males. The 95% confidence ellipse is drawn for each group. 544 Permutational multivariate analysis of variance (PERMANOVA) was performed for statistical comparisons of 545 samples in the two groups. *P* value was adjusted by the Benjamini and Hochberg false discovery rate (FDR). **(B)** 546 Bacterial richness and diversity measured by Chao 1 and Shannon index were calculated at ASV level. Wilcoxon <sup>547</sup>rank-sum test was performed and adjusted by Benjamini and Hochberg false discovery rate (FDR). **(C-F)** PCoA <sup>548</sup>based on Bray-Curtis distances ASV level showed different microbial compositions between groups of 549 CKDF-male and CKDB-male; between HCF-males and HCB-males; between CKDF-female and CKDB-female; 550 between HCF-female and HCB-female. The 95% confidence ellipse is drawn for each group. Permutational 551 multivariate analysis of variance (PERMANOVA) was performed for statistical comparisons of samples in the two <sup>552</sup>groups. *P* value was adjusted by the Benjamini and Hochberg false discovery rate (FDR). **(G)** Comparisons of 553 dissimilarity of Bray-Curtis between females and males' urine and feces in patients and controls group. Wilcoxon 554 rank-sum test was performed and adjusted by Benjamini and Hochberg false discovery rate (FDR). \*\*, FDR < <sup>555</sup>0.01.

556 Abrreviations: CKDF-female: fecal samples provided by females with CKD; CKDF-male: fecal samples provided 557 by males with CKD; CKDB-female: urine samples provided by males with CKD; CKDB-male: urine samples 558 provided by males with CKD; HCF-female: fecal samples provided by females with CKD; HCF-male: fecal 559 samples provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-male: urine 560 samples provided by healthy males.

21

- <sup>562</sup>**Table S1** Comparison of nutrient intake between CKD and HC cohort.
- 563 Student's *t* test on normalized continuous variables, and Wilcoxon rank-sum test on non-normal continuous
- 564 variables.

565

- <sup>566</sup>**Tables S2** Comparison of bacterial phylum abundance between CKDB-male and HCB-male.
- 567 Wilcoxon rank-sum test was applied.
- 568 Abrreviations: CKDB-male: urine samples provided by males with CKD; HCB-male: urine samples provided by
- 569 healthy males.

570

- <sup>571</sup>**Table S3** Comparison of bacterial phylum abundance between CKDB-female and HCB-female.
- 572 Wilcoxon rank-sum test was applied.
- <sup>573</sup>Abrreviations: CKDB-female: urine samples provided by females with CKD; HCB-female: urine samples
- 574 provided by healthy females.

- <sup>576</sup>**Table S4** Comparison of bacterial genus abundance between CKDB-male and HCB-male.
- 577 Wilcoxon rank-sum test was applied.
- 578 Abrreviations: CKDB-male: urine samples provided by males with CKD; HCB-male: urine samples provided by
- 579 healthy males.

580

- <sup>581</sup>**Table S5** Comparison of bacterial genus abundance between CKDB-female and HCB-female.
- 582 Wilcoxon rank-sum test was applied.
- <sup>583</sup>Abrreviations: CKDB-female: urine samples provided by females with CKD; HCB-female: urine samples
- 584 provided by healthy females.
- 585
- <sup>586</sup>**Table S6** Bacteria identified using EQUC.
- 587 Abrreviations: CKDB-male: urine samples provided by males with CKD; CKDB-female: urine samples provided
- <sup>588</sup>by females with CKD; HCB-male: urine samples provided by healthy males; HCB-female: urine samples provided
- 589 by healthy females.

- <sup>591</sup>**Table S7** Comparisons of samples with visible cultures between HCB-male and HCB-female.Pearson Chi-square
- 592 or Fisher's exact test was used
- <sup>593</sup>Abrreviations: CKDB-male: urine samples provided by males with CKD; HCB-male: urine samples provided by
- 594 healthy males.
- 
- <sup>596</sup>**Table S8** Comparisons of samples with visible cultures between HCB-male and HCB-female.Pearson Chi-square
- 597 or Fisher's exact test was used.
- <sup>598</sup>Abrreviations: CKDB-female: urine samples provided by females with CKD; HCB-female: urine samples
- 599 provided by healthy females.
- 600
- <sup>601</sup>**Table S9** Comparison of samples with visible cultures between CKDB-male and HCB-male.
- 602 Pearson Chi-square or Fisher's exact test was used.
- <sup>603</sup>Abrreviations: CKDB-male: bladder urine samples provided by males with CKD; HCB-male: bladder urine
- 604 samples provided by healthy males.
- 605
- <sup>606</sup>**Table S10** Comparison of samples with visible cultures between CKDB-female and HCB-female.
- 607 Pearson Chi-square or Fisher's exact test was used.
- <sup>608</sup>Abrreviations: CKDB-female: bladder urine samples provided by females with CKD; HCB-female: bladder urine
- 609 samples provided by healthy females.
- 
- <sup>611</sup>**Figure S1** Stud design.
- 612 Participants enrollment and study procedures.
- 613 Abrreviations: CKDB: urine samples provided by patients with CKD; HCB: urine samples provided by healthy
- 614 controls; CKDF: fecal samples provided by patients with CKD; HCF: fecal samples provided by healthy controls;
- 615 CKDS: serum samples provided by CKD patient; HCS: serum samples provided by healthy controls.
- 
- <sup>617</sup>**Figure S2** Medication usages on urinary microbiome.
- <sup>618</sup>**(A)** Comparison of urinary microbiome between antihypertensive agent users and non-users; **(B)** Comparison of
- <sup>619</sup>urinary microbiome between glucocorticoid agent users and non-users; **(C)** Comparison of urinary microbiome



- 621 agent users and non-users. Permutational multivariate analysis of variance (PERMANOVA) was performed for
- 622 statistical comparisons of samples in the two groups. *P* value was adjusted by the Benjamini and Hochberg false
- 623 discovery rate (FDR).
- 
- <sup>625</sup>**Figure S3** Urinary microbiome in various CKD stages.
- <sup>626</sup>**(A)** Comparisons of microbial community between patients in CKD stage1-stage5 and controls. Permutational
- 627 multivariate analysis of variance (PERMANOVA) was performed for statistical comparisons of samples in the two
- 628 groups. *P* value was adjusted by the Benjamini and Hochberg false discovery rate (FDR). **(B)** Comparisons of
- 629 microbial richness and diversity between patients in CKD stage1-stage5 and controls. Wilcoxon rank-sum test was
- 630 performed and adjusted by Benjamini and Hochberg false discovery rate (FDR).
- 631

# <sup>632</sup>**References**

















A





−0.4

−0.2

0

 $0.2$ 

0.4









#### Abbreviations

CKDB: CKD patient's bladder; HCB: healthy control's bladder; CKDF: CKD patient's feces; HCF: healthy control's feces; CKDS: CKD patient's serum; HCS: healthy control's serum



ckper

Stage 1

CKDB-Stage 2 + XCB



CKDB-Stage<sup>3</sup>

CKDB-Stage 4 xCB

CHDB-Stage's

